Related Experiment Video
Updated: Jan 7, 2026
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
Published on: December 17, 2021
Mirvetuximab Soravtansine-gynx Induced Anterior Uveitis: A Case Series
Julia Canestraro1,2, Daniel Kowalsky Moskaliuk1, David H Abramson1,2
1Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Purpose:
The more widely known ocular toxicity of Mirvetuximab soravtansine-gynx (MIRV) is keratopathy. Clinical trial data provides little detail on the lesser known toxicity of anterior uveitis from MIRV. We discuss the potential mechanism for this toxicity and provide suggested adjustments to current clinical practice for patients on this drug.
Methods:
This retrospective case series, single center study included 42 consecutive patients treated with MIRV at Memorial Sloan Kettering Cancer Center for High-grade serous ovarian cancer and examined in our ophthalmology department between March 1, 2024 - July 15, 2025.
Results:
Seventeen of forty-two (40%) patients (median age of 69 years) developed keratitis, and three (7.1%) patients, developed grade 1+ bilateral non-granulomatous anterior uveitis on treatment with MIRV. Uveitis was diagnosed after a median of 12 cycles (range 9-14).
Conclusion:
Although a small cohort, our findings suggest that MIRV-induced anterior uveitis is more common than initially thought. Reassuringly, all cases observed have been mild and reversible with topical steroid drops and most patients were able to continue on MIRV (lifesaving) treatment.
Insights
Mirvetuximab soravtansine-gynx (MIRV) can cause anterior uveitis, a less recognized ocular toxicity. This condition appears to be mild and reversible with treatment, allowing patients to continue MIRV therapy.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Mirvetuximab soravtansine-gynx (MIRV) is a treatment for high-grade serous ovarian cancer.
- Keratopathy is a known ocular toxicity of MIRV.
- Anterior uveitis is a less documented ocular toxicity of MIRV.
Purpose of the Study:
- To investigate the incidence and characteristics of anterior uveitis in patients treated with MIRV.
- To discuss the potential mechanism of MIRV-induced anterior uveitis.
- To suggest clinical practice adjustments for managing this toxicity.
Main Methods:
- Retrospective case series of 42 patients with high-grade serous ovarian cancer treated with MIRV.
- Ophthalmology department examinations between March 2024 and July 2025.
- Analysis of patient data for ocular toxicity, specifically anterior uveitis.
Main Results:
- 40% of patients developed keratitis.
- 7.1% of patients (3 out of 42) developed grade 1+ bilateral non-granulomatous anterior uveitis.
- Anterior uveitis was diagnosed after a median of 12 cycles of MIRV treatment.
Conclusions:
- MIRV-induced anterior uveitis may be more common than previously recognized.
- Observed cases of anterior uveitis were mild and reversible with topical steroids.
- Most patients could continue MIRV treatment, indicating its tolerability and efficacy.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
01:25Glaucoma: Overview